CLDN17

Across TCGA pan-cancer cohorts, CLDN17 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated CLDN17 data layer compared with 3 for mutation status.

The strongest signal is observed in uveal melanoma (UVM), where higher CLDN17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN17 expression acts as an unfavorable survival marker, although some lineages such as ESCA and CESC show a favorable association.

UVM, KIRC, and KIRP are the cancer types where CLDN17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Tertile	All	0.220	0.917	<.001	54	view →
KIRC	DFS	Tertile	III,IV	0.272	0.646	.016	54	view →
KIRP	OS	Tertile	II,III,IV	0.381	0.766	.003	42	view →
SKCM	OS	Tertile	IV	0.213	0.775	<.001	40	view →
BLCA	OS	Tertile	All	0.613	0.724	.017	27	view →
PAAD	OS	Tertile	II,III,IV	0.213	0.556	.014	18	view →
SCLC	DFS	Tertile	All	0.192	0.793	.017	18	view →
ESCA	OS	Median	All	1.000	0.693	.038	15	view →
CESC	DFS	Tertile	All	0.827	0.687	.008	14	view →
THCA	DFS	Tertile	IV	0.568	0.963	.004	9	view →
MESO	OS	Tertile	II,III,IV	0.180	0.560	.046	9	view →
LUSC	OS	Median	IV	0.255	0.851	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

CLDN17–UVM (OS)

Open the UVM breakdown →